Director, Clinical Biomarker
Compugen
San Francisco, California, United States
Dr. Liang is currently Director of Clinical Biomarker at Compugen heading implementation of biomarkers in clinical trials to develop drugs targeting immune checkpoints. He brings in 22 years of expertise and leadership in precision medicine, including assay development in research and IVD, and application of genomic and genetic profiling for patient stratification. Before Compugen, he was leading translation of pre-clinical biomarkers in oncology into early phase clinical development as well as their further development into late phase clinical trials at Ipsen, Calithera, and Pharmacyclics/Abbvie. He was also a lead scientist to develop and commercialize many TaqMan PCR and NGS assays at Applied Biosystem/Life Technologies. Before moving to industry. Dr. Liang held an appointment as Assistant Researcher in Brain Tumor Research Center and Department of Neurological Surgery at UCSF.
Disclosure information not submitted.
Clinical Development of Biomarkers in Immune-oncology: Strategies and Challenges
Wednesday, June 21, 2023
2:20 PM - 2:45 PM
